• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Interferon-beta treatment for relapsing multiple sclerosis.
【24h】

Interferon-beta treatment for relapsing multiple sclerosis.

机译：干扰素-β治疗可复发性多发性硬化症。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Recombinant forms of IFN-beta were the first therapeutic intervention found to be effective at interfering with the course of multiple sclerosis (MS), a chronic and debilitating disease affecting the CNS in young adults. OBJECTIVE/METHODS: To examine the application of IFN-beta to MS treatment by a review of relevant literature. RESULTS: The different IFN-beta products available are similar in their clinical effects. However, the response to IFN-beta therapy is only partial and the most efficient individual-specific dose, route and frequency of administration are not elucidated fully. The mechanism of action of IFN-beta in MS is also not understood fully but its immunomodulatory effects are probably more important than its anti-proliferative and antiviral activities. CONCLUSIONS: Although new therapeutic approaches are being sought to better treat MS, IFN-beta remains one of the most recognized and approved worldwide therapeutic options for this disease.
机译：背景：重组形式的IFN-β是第一种有效干预多发性硬化症（MS）病程的治疗性干预措施，多发性硬化症是一种影响年轻人中枢神经系统的慢性衰弱性疾病。目的/方法：通过综述相关文献，探讨IFN-β在MS治疗中的应用。结果：可用的不同IFN-β产品在临床效果上相似。但是，对IFN-β治疗的反应仅是部分的，最有效的个体特异性剂量，给药途径和给药频率尚未完全阐明。 IFN-β在MS中的作用机理也尚未完全了解，但其免疫调节作用可能比其抗增殖和抗病毒活性更为重要。结论：尽管正在寻求新的治疗方法以更好地治疗MS，但是IFN-β仍然是该疾病最广泛认可和认可的全球治疗选择之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号